Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: A randomized clinical trial

International Archives of Medicine

Volumn 6, Issue 1, 2013, Pages

  Amr, Mostafa ^a   Lakhan, Shaheen E ^b,c,e   Sanhan, Sarila ^b   Al Rhaddad, Dahoud ^d   Hassan, Moussa ^d   Thiabh, Mohamed ^d   Shams, Tarek ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b Global Neuroscience Initiative Foundation   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d National center for Mental Health Hospital   (Jordan)

^e not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; COMMON COLD; CONTROLLED STUDY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SOCIAL PSYCHOLOGY; YOUNG ADULT;

EID: 84888989285     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-6-47     Document Type: Article

References (27)

1. Costs of schizophrenia. Knapp M, Br J Psychiatry 1997 171 509 518 10.1192/bjp.171.6.509 9519088 (Pubitemid 27527318)
2. The economic burden of schizophrenia in the United States in 2002. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J, J Clin Psychiatry 2005 66 1122 1129 10.4088/JCP.v66n0906 16187769 (Pubitemid 41442278)
3. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology, J Psychopharmacol 2011 25 567 620 10.1177/0269881110391123 21292923
4. Evidence-based pharmacotherapy of schizophrenia. Leucht S, Heres S, Kissling W, Davis JM, Int J Neuropsychopharmacol 2011 14 269 284 10.1017/S1461145710001380 21208500
5. First and second generation antipsychotics: translating the results from pragmatic trials into clinical practice. Marder SR, Epidemiol Psychiatr Sci 2013 22 1 2 10.1017/S2045796012000698 23253139
6. Olanzapine on trial. Capehart BP, Holsinger T, Am J Psychiatry 1998 155 152 author reply 153-155
7. Risperidone: how good is the evidence for efficacy? Mattes JA, Schizophr Bull 1997 23 155 161 10.1093/schbul/23.1.155 9050121 (Pubitemid 27087915)
8. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B, Am J Psychiatry 2001 158 518 526 10.1176/appi.ajp.158.4.518 11282684 (Pubitemid 32289814)
9. Quetiapine. A review of its use in the management of schizophrenia. Cheer SM, Wagstaff AJ, CNS Drugs 2004 18 173 199 10.2165/00023210-200418030-00004 14871161 (Pubitemid 38293801)
10. Evidence-based pharmacotherapy of schizophrenia. Emsley R, Oosthuizen P, Int J Neuropsychopharmacol 2004 7 219 238 10.1017/S1461145704004171 15043765 (Pubitemid 38823289)
11. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Luis Vazquez-Barquero J, J Clin Psychiatry 2006 67 1511 1521 10.4088/JCP.v67n1004 17107241 (Pubitemid 44787432)
12. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Emsley RA, Raniwalla J, Bailey PJ, Jones AM, Int Clin Psychopharmacol 2000 15 121 131 10.1097/00004850-200015030-00001 10870870 (Pubitemid 30326047)
13. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders Washington, DC: American Psychiatric Publishing, Incorporated 4th edn, text revision. 2000
14. The positive and negative syndrome scale (PANSS) for schizophrenia. Kay SR, Fiszbein A, Opler LA, Schizophr Bull 1987 13 261 276 10.1093/schbul/13.2.261 3616518 (Pubitemid 18039085)
15. The GAF and psychiatric outcome: a descriptive report. Piersma HL, Boes JL, Community Ment Health J 1997 33 35 41 10.1023/A:1022413110345 9061261 (Pubitemid 27108073)
16. A rating scale for extrapyramidal side effects. Simpson GM, Angus JW, Acta Psychiatr Scand Suppl 1970 212 11 19 4917967
17. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP, Int J Neuropsychopharmacol 2005 8 175 182 10.1017/S1461145705005067 15737251 (Pubitemid 40769258)
18. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick ID, Marder SR, J Clin Psychiatry 2005 66 638 641 10.4088/JCP.v66n0515 15889952 (Pubitemid 40733708)
19. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. Purdon SE, Malla A, Labelle A, Lit W, J Psychiatry Neurosci 2001 26 137 149 11291531 (Pubitemid 32373127)
20. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, et al. Lancet 2008 371 1085 1097 10.1016/S0140-6736(08)60486-9 18374841 (Pubitemid 351418005)
21. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, Beaith A, Seida JC, Dursun S, Newton AS, Hartling L, AHRQ Comparative Effectiveness Reviews Rockville (MD): Agency for Healthcare Research and Quality 2012
22. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU, Int J Neuropsychopharmacol 2012 16 1 14 22433185
23. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, Hasan SM, Br J Psychiatry 2006 189 433 440 10.1192/bjp.bp.105.019307 17077434 (Pubitemid 44683176)
24. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Arvanitis LA, Miller BG, Biol Psychiatry 1997 42 233 246 10.1016/S0006-3223(97)00190-X 9270900 (Pubitemid 27325811)
25. Drug treatment of the negative symptoms of schizophrenia. King DJ, Eur Neuropsychopharmacol 1998 8 33 42 10.1016/S0924-977X(97)00041-2 9452938 (Pubitemid 28012858)
26. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Moller HJ, Eur Arch Psychiatry Clin Neurosci 2005 255 432 437 10.1007/s00406-005-0622-6 16267634 (Pubitemid 43029832)
27. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Rabinowitz J, Levine SZ, Barkai O, Davidov O, Schizophr Bull 2009 35 775 788 10.1093/schbul/sbn005 18303093